Glucocorticoid regimens for prevention of graves' ophthalmopathy progression following radioiodine treatment: Systematic review and meta-analysis

Thyroid

Volumn 24, Issue 10, 2014, Pages 1515-1523

  Shiber, Shachaf ^a,b   Stiebel Kalish, Hadas ^a,b   Shimon, Ilan ^a,b   Grossman, Alon ^a,b   Robenshtok, Eyal ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; PLACEBO; PREDNISONE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ANXIETY; COMPARATIVE STUDY; CORTICOSTEROID THERAPY; CUSHINGOID SYNDROME; DISEASE COURSE; ENDOCRINE OPHTHALMOPATHY; HUMAN; HYPERGLYCEMIA; HYPERTHYROIDISM; INSOMNIA; LOW DRUG DOSE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; WEIGHT GAIN; CHI SQUARE DISTRIBUTION; DRUG ADMINISTRATION; GRAVES OPHTHALMOPATHY; PATIENT SELECTION; RISK; RISK ASSESSMENT; TIME; TREATMENT OUTCOME;

CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; GLUCOCORTICOIDS; GRAVES OPHTHALMOPATHY; HUMANS; IODINE RADIOISOTOPES; ODDS RATIO; PATIENT SELECTION; RADIOPHARMACEUTICALS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84911949397     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2014.0218     Document Type: Review

References (26)

1. Sisson JC, Schipper MJ, Nelson CC, Freitas JE, Frueh BR 2008 Radioiodine therapy and Graves' ophthalmopathy. J Nucl Med 49:923-930.
2. Sridama V, DeGroot LJ 1989 Treatment of Graves' disease and the course of ophthalmopathy. Am J Med 87:70-73.
3. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A 1998 Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 338:73-78.
4. Kung AW, Yau CC, Cheng A 1994 The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole. J Clin Endocrinol Metab 79:542-546.
5. Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P 2008 Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol (Oxf) 69:943-950.
6. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A 1992 Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 326:1733-1738.
7. Vestergaard H, Laurberg P 1989 Radioiodine and aggravation of Graves' ophthalmopathy. Lancet 2:47.
8. Bartalena L, Tanda ML, Piantanida E, Lai A 2005 Glucocorticoids and outcome of radioactive iodine therapy for Graves' hyperthyroidism. Eur J Endocrinol 153:13-14.
9. Vannucchi G, Campi I, Covelli D, Dazzi D, Curro N, Simonetta S, Ratiglia R, Beck-Peccoz P, Salvi M 2009 Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. J Clin Endocrinol Metab 94:3381-3386.
10. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A 1989 Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 321:1349-1352.
11. Lai A, Sassi L, Compri E, Marino F, Sivelli P, Piantanida E, Tanda ML, Bartalena L 2010 Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab 95:1333-1337.
12. Jensen BE, Bonnema SJ, Hegedus L 2005 Glucocorticoids do not influence the effect of radioiodine therapy in Graves' disease. Eur J Endocrinol 153:15-21.
13. Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall- Taylor P, Marcocci C, Mourits MP, Perros P, Boboridis K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas G, Lane CM, Lazarus JH, Marino M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM 2008 Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid 18:333-346.
14. Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN 2011 Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 17:456-520.
15. Perros P, Baldeschi L, Boboridis K, Dickinson AJ, Hullo A, Kahaly GJ, Kendall-Taylor P, Krassas GE, Lane CM, Lazarus JH, Marcocci C, Marino M, Mourits MP, Nardi M, Orgiazzi J, Pinchera A, Pitz S, Prummel MF, WiersingaWM 2006 A questionnaire survey on the management of Graves' orbitopathy in Europe. Eur J Endocrinol 155:207-211.
16. Cochrane Handbook for Systematic Reviews of Interventions 5.1.0. Available at: www.cochrane.org/resources/ handbook (accessed January 2014).
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG 2003 Measuring inconsistency in meta-analyses. BMJ 327:557-560.
18. Gamstedt A, Karlsson A 1991 Pretreatment with betamethasone of patients with Graves' disease given radioiodine therapy: thyroid autoantibody responses and outcome of therapy. J Clin Endocrinol Metab 73:125-131.
19. Gamstedt A, Wadman B, Karlsson A 1986 Methimazole, but not betamethasone, prevents 131I treatment-induced rises in thyrotropin receptor autoantibodies in hyperthyroid Graves' disease. J Clin Endocrinol Metab 62:773-777.
20. Vaisman M 1997 Emprego profilático de corticóide na prevençäo da progressä da oftalmopatia de Graves após tratamento do hipertireoidismo com iodo radioativo [Corticosteroids therapy to prevent progression of Graves' ophthalmopathy after treatment of hyperthyroidism with radioiodine.] Folha méd 115:165-167.
21. Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J 2005 A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy. J Clin Endocrinol Metab 90:5321-5323.
22. Traisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, Hallengren B, Hedner P, Lantz M, Nystrom E, Ponjavic V, Taube A, Torring O, Wallin G, Asman P, Lundell G 2009 Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 94:3700-3707.
23. Tallstedt L, Lundell G, Blomgren H, Bring J 1994 Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol 130:494-497.
24. Ponto KA, Zang S, Kahaly GJ 2010 The tale of radioiodine and Graves' orbitopathy. Thyroid 20:785-793.
25. Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, Pariani N, Gallo D, Azzolini C, Ferrario M, Bartalena L 2013 Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center. J Clin Endocrinol Metab 98:1443-1449.
26. Piantanida E, Tanda ML, Lai A, Sassi L, Bartalena L 2013 Prevalence and natural history of Graves' orbitopathy in the XXI century. J Endocrinol Invest 36:444-449.